Senores Pharmaceuticals logo

Senores Pharmaceuticals financials and balance sheet

NSE: SENORESBSE: 544319Pharmaceuticals & BiotechnologySmall Cap

Last close ₹1,215.30up ₹12.70 (1.06%)BSE ₹1,213.90

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,202.60.

52-week range of traded prices to 23 Oct 2026
₹706.00Low, 23 Mar 2026₹1,599.00High, 24 Aug 2026
Market cap
₹5,597 Cr841st largest listed
P/E
42.6
P/B
6.0
Dividend yield
Nonein the last 12 months
ROE
15.3%
ROCE
13.1%
Debt to equity
0.34
Volume, NSE
1,65,74443.3% delivered

2 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Senores Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

The years either side of a change of basis do not compare. From the year to Mar 2026, the company's revenue for that year, ₹633 Cr, differs from its quarters added, ₹650 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue633
  2. Materials and goods−252
  3. Employee costs−112
  4. Other expenses−100
  5. Operating profit168
  6. Depreciation−31
  7. Other income+47
  8. One-off items0.0
  9. Finance costs−25
  10. Profit before tax159
  11. Tax−38
  12. Net profit122

What the company owns

  • Plant, investments and other assets₹1,030 Cr
  • Receivables₹325 Cr
  • Cash and bank₹160 Cr
  • Inventory₹89 Cr

What pays for it: net worth and liabilities

  • Net worth₹965 Cr
  • Borrowings₹327 Cr
  • Owed to suppliers₹235 Cr
  • Other liabilities₹77 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Senores Pharmaceuticals quarterly results

₹ croreMar 2025Filed 10 JunMar 2026Filed 27 May
Revenue from operations398633
309464
Materials and goods bought181252
Employee costs60112
Other expenses67100
Operating profit before depreciation90168
Operating margin22.5%26.6%
Materials, % of revenue45.4%39.8%
Employee costs, % of revenue15.2%17.7%
Other expenses, % of revenue16.9%15.9%
Depreciation and amortisation1731
Operating profit after depreciation73137
Other income1947
Finance costs2225
One-off items00
Profit before tax71159
1238
58122
Other comprehensive income−429
Total comprehensive income55151
Net margin14.6%19.2%
Belonging to the company's shareholders is left blank for the year to Mar 2025: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the company's periods around it state no share for other owners for the gap to belong to.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2025Filed 10 JunMar 2026Filed 27 May
812965
786934
Share capital4646
Reserves740888
Belonging to outside owners of subsidiaries2631
305327
241424
174215
Total assets1,2271,604
504791
722812
Net debt−81167
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2025Filed 10 JunMar 2026Filed 27 May
−4662
−5075
−134−142
Receivables−12−197
Inventories−19−30
Payables−46161
Other working capital−58−75
Tax paid−9−13
Interest paid200
Capital spending158240
Free cash flow−203−178
−429−121
573−1
Dividends paid00
Shares bought back00
Shares issued4720
Net change in cash98−60
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.

₹ per shareMar 2025Filed 10 JunMar 2026Filed 27 May
Earnings per share₹16.12₹26.39
Diluted earnings per share₹16.12₹26.39
Book value per share₹170.71₹202.74
Shareholder yield−18.0%0.0%
Market cap at the year end (₹ crore)2,6283,498

Ratios

Consolidated, years to March.Senores Pharmaceuticals PE ratio and valuation

RatioMar 2025Filed 10 JunMar 2026Filed 27 May
Net profit growth–108.3%
Earnings per share growth–63.7%
Return on equity–14.1%
Return on capital employed6.5%10.6%
Cash conversion−78.7%51.1%
Interest cover3.45.5
Debt to equity0.380.34
Receivable days114187
Inventory days114130
Payable days136340
Cash conversion cycle, days92−24
Working capital days219208
Asset turnover0.320.45
Assets per rupee of net worth1.561.65
Sales per rupee of plant2.001.91
Capital spending to depreciation9.357.68
Plant being built, % of plant in use22.2%5.3%
Revenue growth and operating profit growth are left blank for the year to Mar 2026: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.6%
Cash from operations against operating profit
36.9%
Measure3 years
Return on capital employed, average8.6%
Operating margin, average24.6%
Net margin, average16.9%
Asset turnover, average0.39
Cash conversion cycle, days, average34
Interest cover, average4.4
Debt to equity, average0.36

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations62
Cash from investing−121
Cash from financing−1
Capital spending240
Dividends paid0
Shares bought back0
Shares issued for cash0
Borrowings raised13
Borrowings repaid16

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Altman Z-scorePublished threshold 1.815.695.12
Beneish M-scorePublished threshold −1.78–−1.21
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–12.72
Receivables growth less revenue growthOur threshold 0 percentage points–103.35
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–18.40
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–13.01
Assets under construction, years of additionsOur threshold 2 years of additions–0.11
Effective tax ratePublished threshold 17.16 per cent17.3323.61
Tax charged less tax paid, % of profitOur threshold 10 percentage points4.3415.32
A threshold marked as ours has no published figure; it is the line we read the check against.